Vendor Showcase – Reframing ROI: Unlocking the Value of Integrated CDMO, CRO and Clinical Supply Services in Clinical Trial Execution – Hosted by Thermo Fisher Scientific

What’s the measurable value of working with a single partner across clinical development and manufacturing? In this session, the Tufts Center for the Study of Drug Development shares the results of a new independent study that applies expected Net Present Value (eNPV) modeling to quantify the financial and operational impact of integrating CDMO, CRO, and clinical supply services under one provider. Using Thermo Fisher’s Accelerator™ Drug Development framework as a reference model, the analysis accounts for risk-adjusted progression and real-world complexity. Following the data walkthrough, Luke Wilson, senior director of biotech commercial operations at Thermo Fisher, will share stakeholder perspectives and case examples illustrating how integrated support—particularly at the intersection of clinical operations and supply—can streamline execution, accelerate timelines, and drive stronger ROI across development programs.

Presented by: Luke Wilson, Sr. Director Commercial Operations, Thermo Fisher Scientific, Global Biotech & Ken Getz, Executive Director, Research Professor, Tufts Center of the Study of Drug Development